Daclizumab

{
  "id": "MLC-T-ONC-002266",
  "term": "Daclizumab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to keep the body from rejecting kidney transplants. It is also being studied in the treatment of some types of cancer and other conditions. Daclizumab binds to receptors for a protein called interleukin-2, which are found on some types of immune cells and cancer cells. This may help suppress the body’s immune response and it may help kill cancer cells. Daclizumab is a type of monoclonal antibody. Also called dacliximab and Zenapax.",
    "A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway."
  ],
  "abbreviation": "MOAB anti-Tac",
  "synonyms": [
    "dacliximab",
    "Zenapax",
    "anti-Tac",
    "anti-Tac monoclonal antibody",
    "Anti-Tac Humanized Monoclonal Antibody",
    "Dacliximab"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/daclizumab/"
}